- Previous Close
139.81 - Open
141.64 - Bid 141.03 x 800
- Ask 141.76 x 800
- Day's Range
140.51 - 143.42 - 52 Week Range
78.05 - 168.50 - Volume
659,524 - Avg. Volume
790,856 - Market Cap (intraday)
11.614B - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
15.27 - EPS (TTM)
9.27 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
160.39
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
www.davita.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DVA
View More
Performance Overview: DVA
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVA
View MoreValuation Measures
Market Cap
11.61B
Enterprise Value
22.72B
Trailing P/E
15.26
Forward P/E
12.38
PEG Ratio (5yr expected)
1.07
Price/Sales (ttm)
1.00
Price/Book (mrq)
30.03
Enterprise Value/Revenue
1.79
Enterprise Value/EBITDA
8.81
Financial Highlights
Profitability and Income Statement
Profit Margin
6.53%
Return on Assets (ttm)
6.94%
Return on Equity (ttm)
44.88%
Revenue (ttm)
12.67B
Net Income Avi to Common (ttm)
827.68M
Diluted EPS (ttm)
9.27
Balance Sheet and Cash Flow
Total Cash (mrq)
1.09B
Total Debt/Equity (mrq)
549.55%
Levered Free Cash Flow (ttm)
1.11B
Research Analysis: DVA
View MoreCompany Insights: DVA
DVA does not have Company Insights
Research Reports: DVA
View MoreDaVita Earnings: New Debt Costs Pressure 3Q Results, but 2024 Outlook Remains Intact
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
RatingPrice TargetDaVita Earnings: New Debt Costs Pressure 3Q Results, but 2024 Outlook Remains Intact
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
RatingPrice TargetDaVita Earnings: New Debt Costs Pressure 3Q Results, but 2024 Outlook Remains Intact
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
RatingPrice TargetLowering target price to $166.00
DAVITA INC has an Investment Rating of HOLD; a target price of $166.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice Target